Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
COVID-19
100%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
43%
Hydroxychloroquine
36%
Randomized Trial
35%
Metformin
34%
Placebo
34%
Pre-exposure Prophylaxis (PrEP)
26%
Fluvoxamine
24%
Coronavirus Disease (COVID)
21%
Clinical Trials
21%
Randomized Placebo-controlled Trial
21%
Healthcare Workers
17%
Ivermectin
16%
Cerebrospinal Fluid
15%
Blastomycosis
15%
United States
15%
95% Confidence Interval
14%
Polymerase Chain Reaction
12%
Symptom Severity
11%
Hospitalization
11%
Geographic Distribution
10%
Unvaccinated
10%
Mycobacterium Tuberculosis (M. tb)
10%
Non-hospitalized
9%
Outpatient Treatment
9%
Virus
9%
Randomized Controlled Trial
9%
Viral Load
9%
Antiviral Activity
9%
Twice Daily
8%
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
8%
Ugandan
8%
AIDS/HIV
7%
Long-term Care Facilities
7%
COVID-2
7%
Surrogate Endpoint
7%
Cryptococcal Meningitis
7%
Bacillary Load
7%
Tuberculous Meningitis
7%
Job Roles
7%
Minnesota
7%
Severe Acute Respiratory Syndrome
7%
Early Fungicidal Activity
7%
Histoplasmosis
7%
Clinical Trial Participant
7%
Virological Markers
7%
Xpert MTB/RIF Assay
7%
Clinical Outcomes
7%
Patient-facing
7%
Modern History
7%
Medicine and Dentistry
COVID-19
88%
Severe Acute Respiratory Syndrome Coronavirus 2
59%
Placebo
41%
Outpatient
37%
Glycon
33%
Infection
26%
Fluvoxamine
23%
Hydroxychloroquine
20%
Clinical Trial
19%
Diseases
19%
Controlled Clinical Trial
17%
Health Care Personnel
17%
Randomized Controlled Trial
15%
Post-Exposure Prophylaxis
15%
Ivermectin
15%
Blastomycosis
13%
Randomized Clinical Trials
11%
Virus
10%
Geographic Distribution
9%
Dimorphic Fungal Infection
9%
Coronavirinae
9%
Antivirus Agent
8%
Odds Ratio
8%
Long-Term Care
7%
Histoplasmosis
7%
Dried Blood Spot
7%
Coccidioidomycosis
7%
Post-COVID-19
7%
Virus Nucleocapsid
7%
Prospective Cohort Study
7%
Biological Marker
7%
Cross Sectional Study
7%
Tuberculosis
7%
Pre-Exposure Prophylaxis
7%
Postcovid Syndrome
7%
Polymerase Chain Reaction
6%
Emergency Department
6%
Mycobacteria
5%
Antigen
5%
Hazard Ratio
5%